Lymphoma & Plasma Cell Disorders
News
MRD data added to venetoclax label
The U.S.
From the Journals
TP53 mutation plus complex karyotype equals poor prognosis
The two markers signaled worse overall survival among mantle cell lymphoma patients.
News
New guidelines on antimicrobial prophylaxis
Experts have published updated guidelines on antimicrobial prophylaxis for adults with cancer-related immunosuppression. The guidelines include...
News
First CAR T-cell therapy approved in Canada
Health Canada has authorized use of tisagenlecleucel (Kymriah™), making it the first chimeric antigen receptor (CAR) T-cell therapy to receive...
News
Regimens produce similar results in FL
Rituximab plus lenalidomide had efficacy similar to that of rituximab plus chemotherapy in the treatment of follicular lymphoma (FL) in a phase 3...
News
Ibrutinib maintains efficacy over time
Extended follow-up of the RESONATE-2 trial showed that first-line ibrutinib sustained efficacy in elderly patients with chronic lymphocytic...
From the Journals
RESONATE-2 update: First-line ibrutinib has sustained efficacy in older CLL patients
Adverse events were largely seen during the first year of treatment and decreased over time.
From the Journals
Rituximab/lenalidomide similar to rituximab/chemotherapy for follicular lymphoma
Although the efficacy was similar, safety differed between the two regimens.
From the Journals
Escalating methotrexate may improve survival in T-cell ALL
The findings are based on the Children’s Oncology Group (COG) AALL0434 trial.
News
TYK2 inhibitors could treat ALCL, team says
Preclinical research indicates that TYK2 inhibitors could be effective in treating anaplastic large-cell lymphoma (ALCL). Researchers found...
Latest News
Daratumumab approved in Europe for new myeloma indication
The drug is now authorized for use in combination with bortezomib, melphalan, and prednisone to treat adults with newly diagnosed multiple myeloma...